- Home
- FORA vs BNTC Comparison
FORA vs BNTC Comparison
Compare FORA & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- BNTC
- Stock Information
- Founded
- FORA 2014
- BNTC 1995
- Country
- FORA United States
- BNTC United States
- Employees
- FORA N/A
- BNTC N/A
- Industry
- FORA Computer Software: Prepackaged Software
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- BNTC Health Care
- Exchange
- FORA Nasdaq
- BNTC Nasdaq
- Market Cap
- FORA 63.8M
- BNTC 88.1M
- IPO Year
- FORA N/A
- BNTC N/A
- Fundamental
- Price
- FORA $2.10
- BNTC $10.65
- Analyst Decision
- FORA Strong Buy
- BNTC Strong Buy
- Analyst Count
- FORA 1
- BNTC 5
- Target Price
- FORA $5.00
- BNTC $22.60
- AVG Volume (30 Days)
- FORA 14.2K
- BNTC 39.8K
- Earning Date
- FORA 11-07-2024
- BNTC 11-11-2024
- Dividend Yield
- FORA N/A
- BNTC N/A
- EPS Growth
- FORA N/A
- BNTC N/A
- EPS
- FORA 0.06
- BNTC N/A
- Revenue
- FORA $20,371,880.00
- BNTC N/A
- Revenue This Year
- FORA N/A
- BNTC N/A
- Revenue Next Year
- FORA $10.64
- BNTC N/A
- P/E Ratio
- FORA $36.34
- BNTC N/A
- Revenue Growth
- FORA 6.97
- BNTC N/A
- 52 Week Low
- FORA $2.00
- BNTC $2.69
- 52 Week High
- FORA $4.15
- BNTC $12.89
- Technical
- Relative Strength Index (RSI)
- FORA 38.13
- BNTC 55.32
- Support Level
- FORA $2.05
- BNTC $10.70
- Resistance Level
- FORA $2.16
- BNTC $11.05
- Average True Range (ATR)
- FORA 0.05
- BNTC 0.74
- MACD
- FORA 0.00
- BNTC -0.02
- Stochastic Oscillator
- FORA 31.77
- BNTC 50.94
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.